Rezolute (NASDAQ:RZLT) Releases Earnings Results, Misses Expectations By $0.14 EPS

Rezolute (NASDAQ:RZLT) announced its earnings results on Thursday. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.14), Zacks reports.

Rezolute Stock Performance

Shares of NASDAQ RZLT traded up $0.26 during trading on Friday, reaching $5.08. The stock had a trading volume of 1,514,825 shares, compared to its average volume of 440,479. The firm’s 50 day moving average price is $4.62 and its two-hundred day moving average price is $3.72. Rezolute has a one year low of $0.72 and a one year high of $6.10. The stock has a market cap of $203.89 million, a PE ratio of -4.46 and a beta of 1.18.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $14.00 price objective on shares of Rezolute in a research note on Monday, September 9th. Craig Hallum began coverage on shares of Rezolute in a report on Tuesday, June 4th. They issued a “buy” rating and a $14.00 price objective on the stock. BTIG Research raised their target price on Rezolute from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, September 10th. Guggenheim started coverage on Rezolute in a research note on Tuesday, August 27th. They issued a “buy” rating and a $11.00 price target on the stock. Finally, Maxim Group increased their target price on Rezolute from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Tuesday, August 6th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $11.57.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.